Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Alpha-methylacyl-CoA-racemase (AMACR) is an essential enzyme in the oxidation of bile acid intermediates and branched-chain fatty acids. This study aims to examine the expression pattern, as well as diagnostic and prognostic significance, of AMACR in carcinoma, dysplasia and non-neoplastic epithelium of the stomach. A total of 158 cases, including 66 cases of gastric carcinoma (GC), 48 cases of dysplasia and 44 cases of non-neoplastic gastric mucosa, were examined by immunohistochemistry for AMACR. AMACR expression was divided into two categories: negative (negative-weak staining intensity) and positive (moderate-strong staining intensity). AMACR immunoreactivity was detected in only 2 of 44 (4.5%) cases of non-neoplastic epithelium. A significantly high frequency of AMACR expression was found in 40 of 48 (83.3%) cases of dysplasia and 34 of 66 (51.5%) carcinoma cases compared with cases of non-neoplastic epithelium (p < 0.05). The frequency of AMACR expression was significantly higher in dysplasia than in carcinoma cases (p < 0.05). AMACR expression was higher in intestinal- than diffuse-type GC (p < 0.05). In conclusion, this study suggests that AMACR immunostaining aids in distinguishing malignant or precancerous lesions from reactive epithelial atypia in gastric biopsy specimens. It also suggests that AMACR expression is more likely to be associated with intestinal-type adenocarcinoma in gastric carcinogenesis.